ERBB2 and prostate cancer: We found that while overexpression of ERBB2 increased metastatic potentials specifically for androgen-insensitive human prostate cancer cells, overexpression of RAS did not have similar impacts on metastatic potentials but specifically increased cell motility of c-MYC-overexpressing murine Myc-CaP cells.